Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study

BMC Gastroenterol. 2020 Feb 4;20(1):30. doi: 10.1186/s12876-020-1180-0.

Abstract

Background: One major etiology of hepatic sinusoidal obstruction syndrome (HSOS) in China is the intake of pyrrolizidine alkaloids (PAs). Since PAs-induced HSOS is a rare disease that has not been clearly characterized until now, the aim of this study was to investigate clinical characteristics, CT features, and pathological findings of PA-induced HSOS.

Methods: This retrospective cohort study included 116 patients with PAs-induced HSOS and 68 patients with Budd-Chiari syndrome from Jan 2006 to Sep 2016. We collected medical records of the patients, and reviewed image features of CT, and analyzed pathological findings.

Results: Common clinical manifestations of PAs-induced HSOS were abdominal distention (98.26%), ascites (100%), jaundice (52.94%), abdominal pain (36.36%). Abnormal liver function was observed in most of PAs-induced HSOS. On CT scan, common findings included: ascites, hepatomegaly, the thickening of gallbladder wall, pleural effusion, patchy liver enhancement, and heterogeneous hypoattenuation. Most of the patients had a low ascitic total protein (< 25 g/L) and a high SAAG (≥ 11.0 g/L). In acute stage, pathologic features were massive sinusoidal dilatation, sinusoidal congestion, the extravasation of erythrocytes, hepatocellular necrosis, the accumulation of macrophages, the deposition of hemosiderin. In subacute stage, complete loss of pericentral hepatocytes, sinusoidal dilatation, the deposition of pigment granules were observed.

Conclusions: The PAs-induced HSOS patients displayed distinct clinical characteristics, imaging features, and pathological findings, which provided some evidences for the diagnosis of PAs-induced HSOS.

Trial registration: ChiCTR-DRD-17010709.

Keywords: Ascites; Clinical manifestations; Hepatic sinusoidal obstruction syndrome; Histology; Pyrrolizidine alkaloid.

MeSH terms

  • Aged
  • Animals
  • Ascites / diagnostic imaging
  • Ascites / pathology
  • Female
  • Hepatic Veno-Occlusive Disease / blood
  • Hepatic Veno-Occlusive Disease / chemically induced*
  • Hepatic Veno-Occlusive Disease / diagnostic imaging*
  • Hepatic Veno-Occlusive Disease / pathology
  • Hepatomegaly / diagnostic imaging
  • Hepatomegaly / pathology
  • Humans
  • Liver / diagnostic imaging
  • Liver / pathology
  • Male
  • Middle Aged
  • Monocrotaline / administration & dosage
  • Monocrotaline / adverse effects
  • Pyrrolizidine Alkaloids / administration & dosage
  • Pyrrolizidine Alkaloids / adverse effects*
  • Rats
  • Rats, Sprague-Dawley
  • Retrospective Studies
  • Tomography, X-Ray Computed

Substances

  • Pyrrolizidine Alkaloids
  • Monocrotaline